BioCryst Pharmaceuticals Appoints Salisa Hauptmann, MPH as SVP, Regulatory Affairs

Chartwell Partners is pleased to announce the appointment of Salisa Hauptmann, MPH, as Senior Vice President, Regulatory Affairs for BioCryst Pharmaceuticals, a company pioneering the discovery, development and commercialization of oral, small molecule medicines to treat rare diseases. Salisa brings more than 25 years of global regulatory expertise to BioCryst, including significant work with rare, orphan therapeutics. She will be a tremendous asset to the company as BioCryst launches its first proprietary product, Orladeyo for the treatment of hereditary angioedema (HAE), and progresses an extensive pipeline of future product candidates.